The post Valneva Austria at the Business Run 2024 appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/valneva-austria-at-the-business-run-2024/?lang=de
Die Chemische Industrie auf einen Blick…
The post Valneva Austria at the Business Run 2024 appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/valneva-austria-at-the-business-run-2024/?lang=de
The post World Mosquito Day: How Getting Malaria as a Child Shaped My Life and Gave Purpose to My Career appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/world-mosquito-day-how-getting-malaria-as-a-child-shaped-my-life-and-gave-purpose-to-my-career/?lang=de
The post Mosquito Borne Disease at the Paris Olympics: Reducing the Risk appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/mosquito-borne-disease-at-the-paris-olympics-reducing-the-risk/?lang=de
Der Beitrag HDT Automotive stärkt globales Geschäft mit Abschluss der Akquisition des Hauptsitzes und ausgewählter Geschäftsaktivitäten der Veritas AG erschien zuerst auf Veritas AG.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.veritas.ag/hdt-automotive-staerkt-globales-geschaeft-mit-abschluss-der-akquisition-des-hauptsitzes-und-ausgewaehlter-geschaeftsaktivitaeten-der-veritas-ag/
The post Valneva Sweden at the opening ceremony for International Vaccine Institute’s new European office in Stockholm appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/valneva-sweden_ivi_opening_ceremony/?lang=de
The post Earth Day 2024: Our Commitment to Sustainability appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/earth-day-2024-our-commitment-to-sustainability/?lang=de
Evotec SE today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s Management Board, bringing with her a wealth of experience and expertise in Human Resources leadership. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-welcomes-aurelie-dalbiez-as-chief-people-officer-6380
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/-6378
The post Valneva Austria recognized once again as a family-friendly employer with the “Familie und Beruf” certificate appeared first on Valneva.
Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://valneva.com/valneva-austria-recognized-once-again-as-a-family-friendly-employer-with-the-familie-und-beruf-certificate/?lang=de
Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life Sciences and Deep Track Capital as well as all existing investors, including Andera Partners, BioMedPartners, Fund+, Bayern Kapital (with ScaleUp-Fonds Bayern), Evotec, coparion, Seventure Partners, OCCIDENT and High-Tech Gründerfonds (HTGF). Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/tubulis-closes-upsized-eur128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline-6376